Matches
From your records, pre-screened. Add internal candidates to a study, or refer external ones out.
RM
R.M.
54· Female
Your study
Type 2 diabetes (HbA1c 8.1%), BMI 33, on metformin. Coming in Thu for a routine follow-up.
Novel Digital Patient-Reported Outcomes Tool for Diabetes Management
NCT05884775
HbA1c 8.1% is inside the 7.0-10.5% inclusion window · BMI 33 meets the ≥27 kg/m² requirement
Upcoming visit · Thu 10:30
Likely eligible
DO
D.O.
47· Male
Your study
Obesity (BMI 36), pre-diabetes, hypertension controlled on lisinopril. Seen last month.
Carotid Implants for PreveNtion of STrokE ReCurrEnce From Large Vessel Occlusion in Atrial Fibrillation Patients Treated With Oral Anticoagulation
NCT05723926
BMI 36 meets the obesity inclusion · No diabetes diagnosis (matches non-diabetic cohort)
Problem list · seen 3w ago
Likely eligible
EC
E.C.
72· Female
Partner site
Mild cognitive impairment, MMSE 25, family history of Alzheimer's. Followed in clinic.
Anti-Amyloid Infusion in Early Alzheimer's Disease
Sunnybrook Health Sciences Centre · Toronto, ON
MCI with documented memory decline · Age within 55-80 window
Problem list
Likely eligible
AL
A.L.
43· Female
Your study
Obesity (BMI 38), PCOS, no diabetes. New patient this week.
Tirzepatide vs Placebo for Type 2 Diabetes and Weight
NCT06034262
BMI 38 well within inclusion · Adult, non-diabetic
New this week
Likely eligible
TW
T.W.
39· Male
Partner site
Moderate-to-severe plaque psoriasis, ~12% BSA, failed two topicals.
Once-Daily Oral Therapy for Moderate-to-Severe Plaque Psoriasis
Toronto Dermatology Research · Toronto, ON
BSA ≥10% meets severity threshold · Failed prior topical therapy
Upcoming visit · next week
Likely eligible
PR
P.R.
50· Female
Your study
Prediabetes (A1c 6.1%), obesity BMI 32, hypertension. Flagged on recent labs.
Novel Digital Patient-Reported Outcomes Tool for Diabetes Management
NCT05884775
BMI 32 meets obesity inclusion · No diabetes diagnosis
Recent lab flag
Likely eligible
SK
S.K.
61· Female
Your study
NAFLD noted on ultrasound, elevated ALT, BMI 31, type 2 diabetes.
Change of Adipose Tissues and Triglyceride After Bariatric Surgery or Life-style Intervention
NCT03875625
Imaging-confirmed hepatic steatosis · BMI 31, T2D present
Upcoming visit · next Tue
Possible
JT
J.T.
58· Male
Your study
Type 2 diabetes 9 years, HbA1c 9.2%, BMI 29, on metformin + SGLT2i.
Clinical Trial on Agitation in Alzheimer's Dementia
NCT05543681
T2D on stable background therapy · BMI 29
Problem list
Possible
CN
C.N.
63· Male
Your study
Type 2 diabetes 11 years, BMI 30, chronic kidney disease stage 2.
Carotid Implants for PreveNtion of STrokE ReCurrEnce From Large Vessel Occlusion in Atrial Fibrillation Patients Treated With Oral Anticoagulation
NCT05723926
T2D on stable therapy · BMI in range
Upcoming visit · Mon
Possible
MP
M.P.
66· Male
Your study
Type 2 diabetes, BMI 34, prior MI (2019), coming in for meds review.
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
NCT07321886
T2D and BMI meet inclusion
Upcoming visit · Fri
Possible
WG
W.G.
56· Male
Your study
Added to study
Biopsy-confirmed MASH (NASH), fibrosis stage F2, type 2 diabetes, BMI 33.
Clinical Trial on Agitation in Alzheimer's Dementia
NCT05543681
Biopsy-confirmed steatohepatitis at F2 · T2D and BMI meet inclusion
Hepatology referral
Likely eligible
HB
H.B.
41· Female
Your study
Passed
Obesity (BMI 41), obstructive sleep apnea on CPAP, no diabetes. New patient.
Change of Adipose Tissues and Triglyceride After Bariatric Surgery or Life-style Intervention
NCT03875625
BMI 41 well above inclusion threshold · Adult, non-diabetic cohort
New patient this week
Likely eligible
GR
G.R.
45· Female
Partner site
Referral sent
Crohn's disease, moderate activity despite azathioprine. Recent flare.
Investigational Biologic for Moderate-to-Severe Crohn's Disease
Mount Sinai IBD Centre · Toronto, ON
Confirmed Crohn's, moderate activity · Inadequate response to immunomodulator
Problem list · flare 2w ago
Possible